Katie Koziara Katie is a director of public affairs at PhRMA focusing on the cost and value of medicines. She previously ran the social media strategy for a D.C.-based non-profit working on federal management and leadership issues. Outside the office, Katie can be found running on the mall, brunching with friends and cheering on the Michigan Wolverines.
Recent Posts
Cancer medicines cost twice as much at hospitals, study finds
By Katie Koziara | January 21, 2020
Cancer medicines cost nearly twice as much in hospital outpatient facilities than in physician offices in the commercial market, according to a new study from the Employee Benefit Research...
Read More
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
By Katie Koziara | November 4, 2019
A new analysis from Xcenda applied the Institute for Clinical and Economic Review’s (ICER) value assessments to state Medicaid programs in California, Massachusetts, Maryland, Nevada and New York....
Read More
Hospitals make 9 times more than physicians’ offices on provider-administered medicines
By Katie Koziara | September 10, 2019
A new study, conducted by the Partnership for Health Analytic Research (PHAR), found that hospitals retained 91% of the total profit on physician-administered medicines in the commercial market...
Read More
Ask About Adherence: Hepatitis C cures will save Medicaid $12 billion by 2022
By Katie Koziara | June 21, 2019
Ask About Adherence is a blog series featuring Q&A’s with experts and new medication adherence resources. In this post, we feature a recent study on the savings associated with new hepatitis C...
Read More
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
By Katie Koziara | March 20, 2019
A new analysis from Xcenda found that if Medicaid were to use one-size-fits-all value assessments like the Institute for Clinical and Economic Review’s (ICER) framework as the basis for accessing...
Read More
Value assessments should include all the outcomes that matter to patients and families
By Katie Koziara | February 20, 2019
Value assessments are an important tool in moving toward better, more affordable health care. When it comes to assessing the value of medicines, we need approaches that reflect what matters to...
Read More
Coupons allow patients to remain on medicines in spite of high cost sharing and deductibles
By Katie Koziara | October 4, 2018
According to a new report by IQVIA Institute for Human Data Science, more and more patients are asked to pay high cost sharing due to changes in benefit design. Previous analysis has shown that...
Read More
Event tomorrow: Leaders convene to discuss solutions to advance value-driven health care
By Katie Koziara | October 2, 2018
Tomorrow, October 3, PhRMA will convene health care leaders for a discussion on how we can move our health care system toward one focused on value rather than volume, ensuring patients can access...
Read More
Aspen Spotlight Health: Discussing the forefront of innovation
By Katie Koziara | June 21, 2018
For the second year in a row, PhRMA is proud to participate in Aspen’s Spotlight Health Conference. As the opening session of Aspen Ideas Festival, Spotlight Health welcomes over 1,500 experts and...
Read More
Event tomorrow: Making the biopharmaceutical supply chain work for patients
By Katie Koziara | May 2, 2018
In the U.S. health care system, the complex process of delivering medicines to patients is highly intermediated and involves many entities, including insurance companies, pharmacy benefit managers...
Read More
Medicare Monday (100)
340B Spotlight (46)
Cost & Consequence (0)
